DexCom is a medical device company primarily focused on the design, development and commercialization of continuous glucose monitoring systems for use by people with diabetes and by healthcare providers. The company's products include: DecCom G6?, which allows the company's transmitter to run an algorithm to generate a glucose value and to communicate to a patient's mobile device; DexCom G4? PLATINUM, which is used to adjust therapy and to educate and motivate patients to modify their behavior after viewing the effects that specific foods, exercise, stress and medications have on their glucose levels; and DexCom Share?, which transmits glucose information to the mobile devices of designated recipients.

Eli Lilly and Company discovers, develops, manufactures, and markets products in a single business segment: human pharmaceutical products. The company's human pharmaceutical products include: diabetes and other endocrinology products, immunology products, neuroscience products, oncology products, and other products. The company's diabetes and other endocrinology products include: Baqsimi? and Basaglar?. The company's immunology products include: Olumiant? and Taltz?. The company's neuroscience products include: Cymbalta? and Emgality?. The company's oncology products include: Alimta?, Cyramza?, Erbitux? and Verzenio?. The company's other products include: Cialis?.

Insulet is engaged in the development, manufacturing and sale of its Omnipod? System, an insulin delivery system for people with insulin-dependent diabetes, which consists of two product lines: the Omnipod Insulin Management System and Omnipod DASH? Insulin Management System. The Omnipod System features a self-adhesive disposable tubeless Pod, which is worn on the body and provides up to three days of non-stop insulin delivery without the need to see or handle a needle, and a handheld Personal Diabetes Manager. The Omnipod System communicates wirelessly, provides for automated cannula insertion and eliminates the need for multiple daily injection therapy or the use of pump and tubing.

Oramed Pharmaceuticals is a pharmaceutical company. The company is engaged in the research and development of pharmaceutical solutions, including an oral insulin capsule to be used for the treatment of individuals with diabetes, and the use of orally ingestible capsules or pills for delivery of other polypeptides. The company's primary product ORMD-0801, is an orally ingestible insulin capsule for the treatment of diabetes. In addition to its key product, the ORMD-0801 insulin capsule, the company is using its technology for an orally ingestible GLP-1 capsule, or ORMD-0901. The company is also developing a new drug candidate, a weight loss treatment in the form of an oral leptin capsule.

Sanofi is an integrated, global healthcare company focused on patient needs and engaged in the research, development, manufacture and marketing of healthcare products. Two segments make up Co.'s business: Pharmaceuticals and Vaccines. The Pharmaceuticals segment covers research, development, production and marketing of medicines, consisting of flagship products, plus a broad range of prescription medicines, generic medicines, and consumer health products. The Vaccines segment includes research, development, production and marketing of vaccines in five areas: pediatric vaccines, influenza vaccines, adult and adolescent booster vaccines, meningitis vaccines, and travel and endemic vaccines.

Senseonics Holdings is a medical technology company focused on the development and commercialization of an implantable continuous glucose monitoring (CGM) system to improve the lives of people with diabetes. The company's Eversense and Eversense XL CGM systems are designed to measure glucose levels in people with diabetes via an under-the-skin sensor, a removable and rechargeable smart transmitter, and an app for real-time diabetes monitoring and management for a period of up to 90 and 180 days, respectively. The Eversense system can be used as a therapeutic CGM in the United States to replace fingerstick blood glucose measurement to make treatment decisions, including insulin dosing.

Tandem Diabetes Care is a medical device company engaged in designing, developing and commercializing products for people with insulin-dependent diabetes. The company primarily focuses on the t:slim X2 Insulin Delivery System, or t:slim X2, the company's key pump platform that is capable of remote feature updates and designed to display continuous glucose monitoring sensor information directly on the pump home screen. In addition to selling insulin pumps, the company sells disposable products that are used together with the pumps and are replaced every few days, including cartridges for storing and delivering insulin, and infusion sets that connect the insulin pump to a user's body.

Teladoc Health is a provider of virtual healthcare services. The company provides virtual access to care and capabilities, with a portfolio of services and solutions covering medical subspecialties from non-urgent, episodic needs like flu and upper respiratory infections, to medical conditions like cancer and congestive heart failure. In its behavioral health business, branded BetterHelp, the company serves individuals in the direct-to-consumer market and through business partnerships with other brands. The company's consumer brands, which include Teladoc, Advance Medical, Best Doctors, BetterHelp and HealthiestYou, deliver access to advice and resolution to an array of healthcare needs.

Tiziana Life Sciences is a biotechnology company focused on the discovery and development of therapeutics for cancers and immune diseases. Co.'s pipeline of assets include clinical stage development therapeutic candidates in both oncology and immunology, as well as a pre-clinical drug discovery pipeline of small molecule New Chemical Entities. Co. has two lead clinical programs: Foralumab (TZLS-401 / NI-0401), an anti-CD3 monoclonal antibody that Co. is evaluating in non-alcoholic steatohepatitis and graft vs host disease; and Milciclib (TZLS-201), which is in clinical trials for thymic carcinoma (thymoma) in patients previously treated with chemotherapy, and for hepatocellular carcinoma.

Vertex Pharmaceuticals is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and developing research and development programs in other indications. The company's marketed products are TRIKAFTA (elexacaftor/tezacaftor/ivacaftor and ivacaftor), SYMDEKO/SYMKEVI (tezacaftor in combination with ivacaftor), ORKAMBI (lumacaftor in combination with ivacaftor) and KALYDECO (ivacaftor), which are approved to treat patients with CF who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene. The company is evaluating CTX001, a genetic therapy as a potential treatment for sickle cell disease and beta-thalassemia.